Indivior Pharmaceuticals, Inc. (INDV) fair value analysis

Nasdaq · Updated 2026-09-07

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing medications for addiction, pain, and other therapeutic areas. The company operates globally with a presence in multiple countries to manufacture, market, and distribute its pharmaceutical products.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, INDV is trading at more than a 25% discount to estimated fair value.

INDV currently ranks #30 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $37.37
Sector: Healthcare
12-month range: $23.46–$40.25

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Oversold
50/200-day trend: Mixed
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for INDV

Our model validated 13 trailing price-to-earnings windows for INDV, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $23.46–$40.25.
The 14-day relative strength index sits at an oversold 29.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for INDV
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

What people are saying

Follow the INDV conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is INDV stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), INDV is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is INDV's TickrTrends verdict?

INDV's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does INDV compare to other Healthcare stocks?

INDV ranks #30 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is INDV overbought or oversold?

INDV's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.

All Healthcare fair-value coverage →

Head-to-head comparisons

INDV vs AVAH · INDV vs CI · INDV vs GEHC · INDV vs HSTM · INDV vs IDXX